 | • レポートコード：GIR-107A12288 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、血液がん用遺伝子改変免疫療法のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。血液がん用遺伝子改変免疫療法の種類別市場規模（CAR T細胞療法、TCR T細胞療法）、用途別市場規模（急性リンパ性白血病、慢性リンパ性白血病、B細胞リンパ腫、多発性骨髄腫、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・血液がん用遺伝子改変免疫療法の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Novartis、Kite Pharma、Juno Therapeutics、Cellectis、Ziopharm Oncology、Celyad、Bluebird Bio、Bellicum Pharmaceuticals、Mustang Bio ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：CAR T細胞療法、TCR T細胞療法 ・用途別分析2016年-2026年：急性リンパ性白血病、慢性リンパ性白血病、B細胞リンパ腫、多発性骨髄腫、その他 ・血液がん用遺伝子改変免疫療法の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・血液がん用遺伝子改変免疫療法のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・血液がん用遺伝子改変免疫療法のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・血液がん用遺伝子改変免疫療法の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・血液がん用遺伝子改変免疫療法の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Gene Modifying Immunotherapy for Blood Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Gene Modifying Immunotherapy for Blood Cancer size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Gene Modifying Immunotherapy for Blood Cancer market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Gene Modifying Immunotherapy for Blood Cancer market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
CAR T-cell Therapy
TCR T-cell Therapy
Market segment by Application, can be divided into
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other
Market segment by players, this report covers
Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Gene Modifying Immunotherapy for Blood Cancer
1.2 Classification of Gene Modifying Immunotherapy for Blood Cancer by Type
1.2.1 Overview: Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type in 2020
1.2.3 CAR T-cell Therapy
1.2.4 TCR T-cell Therapy
1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market by Application
1.3.1 Overview: Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Acute Lymphocytic Leukemia
1.3.3 Chronic Lymphocytic Leukemia
1.3.4 B Cell Lymphoma
1.3.5 Multiple Myeloma
1.3.6 Other
1.4 Global Gene Modifying Immunotherapy for Blood Cancer Market Size & Forecast
1.5 Global Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast by Region
1.5.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Region, (2016-2021)
1.5.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size and Prospect (2016-2026)
1.5.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size and Prospect (2016-2026)
1.5.6 South America Gene Modifying Immunotherapy for Blood Cancer Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Gene Modifying Immunotherapy for Blood Cancer Market Drivers
1.6.2 Gene Modifying Immunotherapy for Blood Cancer Market Restraints
1.6.3 Gene Modifying Immunotherapy for Blood Cancer Trends Analysis
2 Company Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
2.1.4 Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Novartis Recent Developments and Future Plans
2.2 Kite Pharma
2.2.1 Kite Pharma Details
2.2.2 Kite Pharma Major Business
2.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
2.2.4 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Kite Pharma Recent Developments and Future Plans
2.3 Juno Therapeutics
2.3.1 Juno Therapeutics Details
2.3.2 Juno Therapeutics Major Business
2.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
2.3.4 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Juno Therapeutics Recent Developments and Future Plans
2.4 Cellectis
2.4.1 Cellectis Details
2.4.2 Cellectis Major Business
2.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
2.4.4 Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Cellectis Recent Developments and Future Plans
2.5 Ziopharm Oncology
2.5.1 Ziopharm Oncology Details
2.5.2 Ziopharm Oncology Major Business
2.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
2.5.4 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Ziopharm Oncology Recent Developments and Future Plans
2.6 Celyad
2.6.1 Celyad Details
2.6.2 Celyad Major Business
2.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
2.6.4 Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Celyad Recent Developments and Future Plans
2.7 Bluebird Bio
2.7.1 Bluebird Bio Details
2.7.2 Bluebird Bio Major Business
2.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
2.7.4 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Bluebird Bio Recent Developments and Future Plans
2.8 Bellicum Pharmaceuticals
2.8.1 Bellicum Pharmaceuticals Details
2.8.2 Bellicum Pharmaceuticals Major Business
2.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
2.8.4 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Bellicum Pharmaceuticals Recent Developments and Future Plans
2.9 Mustang Bio
2.9.1 Mustang Bio Details
2.9.2 Mustang Bio Major Business
2.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
2.9.4 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Mustang Bio Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Gene Modifying Immunotherapy for Blood Cancer Players Market Share
3.2.2 Top 10 Gene Modifying Immunotherapy for Blood Cancer Players Market Share
3.2.3 Market Competition Trend
3.3 Gene Modifying Immunotherapy for Blood Cancer Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue and Market Share by Type (2016-2021)
4.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Application (2016-2021)
5.2 Gene Modifying Immunotherapy for Blood Cancer Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2016-2026)
6.2 North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2026)
6.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
6.3.1 North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2016-2026)
6.3.2 United States Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
6.3.3 Canada Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
6.3.4 Mexico Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2016-2026)
7.2 Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2026)
7.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
7.3.1 Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2016-2026)
7.3.2 Germany Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
7.3.3 France Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
7.3.5 Russia Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
7.3.6 Italy Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2016-2026)
8.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2026)
8.3 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region
8.3.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Region (2016-2026)
8.3.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
8.3.3 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
8.3.4 South Korea Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
8.3.5 India Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
8.3.7 Australia Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2016-2026)
9.2 South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2026)
9.3 South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
9.3.1 South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2016-2026)
9.3.2 Brazil Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
9.3.3 Argentina Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2016-2026)
10.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2026)
10.3 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
10.3.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2016-2026)
10.3.2 Turkey Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
10.3.4 UAE Gene Modifying Immunotherapy for Blood Cancer Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Gene Modifying Immunotherapy for Blood Cancer Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million) by Region (2016-2021)
Table 5. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Region (2021-2026)
Table 6. Novartis Corporate Information, Head Office, and Major Competitors
Table 7. Novartis Major Business
Table 8. Novartis Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
Table 9. Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Kite Pharma Corporate Information, Head Office, and Major Competitors
Table 11. Kite Pharma Major Business
Table 12. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
Table 13. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Juno Therapeutics Corporate Information, Head Office, and Major Competitors
Table 15. Juno Therapeutics Major Business
Table 16. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
Table 17. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Cellectis Corporate Information, Head Office, and Major Competitors
Table 19. Cellectis Major Business
Table 20. Cellectis Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
Table 21. Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Ziopharm Oncology Corporate Information, Head Office, and Major Competitors
Table 23. Ziopharm Oncology Major Business
Table 24. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
Table 25. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Celyad Corporate Information, Head Office, and Major Competitors
Table 27. Celyad Major Business
Table 28. Celyad Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
Table 29. Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Bluebird Bio Corporate Information, Head Office, and Major Competitors
Table 31. Bluebird Bio Major Business
Table 32. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
Table 33. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Bellicum Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. Bellicum Pharmaceuticals Major Business
Table 36. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
Table 37. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Mustang Bio Corporate Information, Head Office, and Major Competitors
Table 39. Mustang Bio Major Business
Table 40. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product and Solutions
Table 41. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Global Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million) by Players (2019-2021)
Table 43. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Players (2019-2021)
Table 44. Breakdown of Gene Modifying Immunotherapy for Blood Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Gene Modifying Immunotherapy for Blood Cancer Players Head Office, Products and Services Provided
Table 46. Gene Modifying Immunotherapy for Blood Cancer Mergers & Acquisitions in the Past Five Years
Table 47. Gene Modifying Immunotherapy for Blood Cancer New Entrants and Expansion Plans
Table 48. Global Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million) by Type (2016-2021)
Table 49. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Type (2016-2021)
Table 50. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Forecast by Type (2021-2026)
Table 51. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2021)
Table 52. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Forecast by Application (2021-2026)
Table 53. North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2016-2021) & (USD Million)
Table 54. North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2021-2026) & (USD Million)
Table 55. North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2021) & (USD Million)
Table 56. North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2021-2026) & (USD Million)
Table 57. North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2016-2021) & (USD Million)
Table 58. North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2021-2026) & (USD Million)
Table 59. Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2016-2021) & (USD Million)
Table 60. Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2021-2026) & (USD Million)
Table 61. Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2021) & (USD Million)
Table 62. Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2021-2026) & (USD Million)
Table 63. Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2016-2021) & (USD Million)
Table 64. Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2021-2026) & (USD Million)
Table 65. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2016-2021) & (USD Million)
Table 66. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2021-2026) & (USD Million)
Table 67. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2021) & (USD Million)
Table 68. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2021-2026) & (USD Million)
Table 69. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Region (2016-2021) & (USD Million)
Table 70. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Region (2021-2026) & (USD Million)
Table 71. South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2016-2021) & (USD Million)
Table 72. South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2021-2026) & (USD Million)
Table 73. South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2021) & (USD Million)
Table 74. South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2021-2026) & (USD Million)
Table 75. South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2016-2021) & (USD Million)
Table 76. South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2016-2021) & (USD Million)
Table 78. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue by Type (2021-2026) & (USD Million)
Table 79. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2016-2021) & (USD Million)
Table 80. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue by Application (2021-2026) & (USD Million)
Table 81. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2016-2021) & (USD Million)
Table 82. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Gene Modifying Immunotherapy for Blood Cancer Picture
Figure 2. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type in 2020
Figure 3. CAR T-cell Therapy
Figure 4. TCR T-cell Therapy
Figure 5. Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Application in 2020
Figure 6. Acute Lymphocytic Leukemia Picture
Figure 7. Chronic Lymphocytic Leukemia Picture
Figure 8. B Cell Lymphoma Picture
Figure 9. Multiple Myeloma Picture
Figure 10. Other Picture
Figure 11. Global Gene Modifying Immunotherapy for Blood Cancer Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Gene Modifying Immunotherapy for Blood Cancer Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Region (2016-2026)
Figure 14. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Region in 2020
Figure 15. North America Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Gene Modifying Immunotherapy for Blood Cancer Market Drivers
Figure 21. Gene Modifying Immunotherapy for Blood Cancer Market Restraints
Figure 22. Gene Modifying Immunotherapy for Blood Cancer Market Trends
Figure 23. Novartis Recent Developments and Future Plans
Figure 24. Kite Pharma Recent Developments and Future Plans
Figure 25. Juno Therapeutics Recent Developments and Future Plans
Figure 26. Cellectis Recent Developments and Future Plans
Figure 27. Ziopharm Oncology Recent Developments and Future Plans
Figure 28. Celyad Recent Developments and Future Plans
Figure 29. Bluebird Bio Recent Developments and Future Plans
Figure 30. Bellicum Pharmaceuticals Recent Developments and Future Plans
Figure 31. Mustang Bio Recent Developments and Future Plans
Figure 32. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Players in 2020
Figure 33. Gene Modifying Immunotherapy for Blood Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share in 2020
Figure 35. Global Top 10 Players Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Type in 2020
Figure 38. Global Gene Modifying Immunotherapy for Blood Cancer Market Share Forecast by Type (2021-2026)
Figure 39. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Application in 2020
Figure 40. Global Gene Modifying Immunotherapy for Blood Cancer Market Share Forecast by Application (2021-2026)
Figure 41. North America Gene Modifying Immunotherapy for Blood Cancer Sales Market Share by Type (2016-2026)
Figure 42. North America Gene Modifying Immunotherapy for Blood Cancer Sales Market Share by Application (2016-2026)
Figure 43. North America Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Country (2016-2026)
Figure 44. United States Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Gene Modifying Immunotherapy for Blood Cancer Sales Market Share by Type (2016-2026)
Figure 48. Europe Gene Modifying Immunotherapy for Blood Cancer Sales Market Share by Application (2016-2026)
Figure 49. Europe Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Country (2016-2026)
Figure 50. Germany Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Region (2016-2026)
Figure 58. China Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Gene Modifying Immunotherapy for Blood Cancer Sales Market Share by Type (2016-2026)
Figure 65. South America Gene Modifying Immunotherapy for Blood Cancer Sales Market Share by Application (2016-2026)
Figure 66. South America Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
世界のがん治療用遺伝子治療市場予測（～2024年） Gene therapy is the therapeutic delivery of nucleic acid into a patient's cells as a drug to treat disease. Research in gene therapy for cancer is currently focused in multiple areas, including genetically engineered viruses that directly kill cancer cells, gene transfer to alter the abnormal functi…- 特定がん免疫療法薬市場：世界及び中国市場分析・予測（～2024年） Specific Cancer Immunotherapy Drugs Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Specific Cancer Immunotherapy Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of th…
- 世界の血液がん治療市場 2021：企業別、地域別、種類・用途別 The Blood Cancer Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regul…
- 世界の遺伝子治療市場予測（～2024年） Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, t…
- 世界のCAR T細胞免疫療法市場予測（～2024年） CAR T-Cell Immunotherapy is a new type of cancer treatment. This emerging treatment represents one of the biggest breakthroughs since the introduction of chemotherapy. T cells is a type of white blood cell extracted from the patient’s blood by doctors, and added an artificial receptor to their surfa…